Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

NCT00179725 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: CC-5013
DRUG: liposomal doxorubicin

Sponsor

Celgene Corporation

Collaborators

[object Object]